Transgene 'delay' with lung cancer vaccine not necessarily bad
This article was originally published in Scrip
Executive Summary
Transgene is facing a delay with its lung cancer vaccine TG4010, the subject of an option agreement with Novartis, but the development does not necessarily spell bad news. Transgene has reported that the number of disease-progression events required per protocol to perform the progression-free survival (PFS) analysis for the Phase IIb part of the TIME study was reached later than had been expected. This has resulted in a delay in the time to topline data, which had been due this quarter.